Stradefy Biosciences is pioneering next-generation polymer nanoparticles, rationally engineered for cellular bioadhesion, uptake and therapeutic payload release. Lead candidates, initially targeting unmet needs in the oncology and immunology areas, have demonstrated in vivo proof of efficacy and are advancing to the IND stage. Stradefy was co-founded by Mark Saltzman, Michael Girardi, Yale University and Elm Street Ventures.
Company Details
- Employees
- 2
- Founded
- -
- Address
- New Haven, Ct, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- New Haven.
- HQ
- New Haven, CT
Stradefy Biosciences Questions
Stradefy Biosciences's LinkedIn profile is https://www.linkedin.com/company/stradefy-biosciences
Stradefy Biosciences has
2 employees.
View email and phone details for 2
employees at Stradefy Biosciences.
Stradefy Biosciences's industry is
Biotechnology Research
Stradefy Biosciences's top competitors are
Halda Therapeutics,
D2b3,
Bexorg, Inc.,
Aeglea Biotherapeutics,
Yale Ventures,
Health Equity Forum,
Ensight-Ai,
Arvinas,
Artelis Biopharma,
Rho Bio.
Stradefy Biosciences's categories are Biotechnology Research
Stradefy Biosciences's founding year is 2019
